| Compounds | Topics | Title | Date |
|---|---|---|---|
| cannabis | autism via review | Medical cannabis for paediatric developmental-behavioural and psychiatric disorders | Apr 2018 |
| In summary, MC has potential as a therapeutic option in the management of paediatric mental health symptoms; however, the evidence to support its use for these patients is not yet in. There is an urgent need to conduct well-designed trials of pharmaceutical-grade MC products in children with behavioural and psychiatric disorders. In the meantime, paediatricians should counsel caution in relation to MC treatment for these indications. | |||
| CBDV | autism in rats via experiment | Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats | Aug 2019 |
| Here, we investigated the ability of CBDV treatment to reverse or prevent ASD-like behaviors in male rats prenatally exposed to valproic acid (VPA; 500 mg/kg i.p.; gestation day 12.5). The offspring received CBDV according to two different protocols | |||
| CBD | autism via review | Oral cannabis extracts as a promising treatment for the core symptoms of autism spectrum disorder: Preliminary experience in Chilean patients | Oct 2017 |
| Preclinical studies and several anecdotal case reports suggest a dysfunctional endocannabinoid system implicated in Autism Spectrum Disorder (ASD). | |||
| CBD | autism in humans via trial (n=188) | Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy | Jan 2019 |
|
Ingestion Method: cannabis oil containing 30% CBD and 1.5% THC Positive After six months of treatment 82.4% of patients (155) were in active treatment and 60.0% (93) have been assessed; 28 patients (30.1%) reported a significant improvement, 50 (53.7%) moderate, 6 (6.4%) slight and 8 (8.6%) had no change in their condition. | |||
| cannabinoids | autism via review | Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention | Jun 2017 |
| The growing number of medical benefits of ES, such as their ability to regulate processes like neuroinflammation, neurogenesis and memory, raise the question of their potential role as a preventive treatment of ASD. | |||
| ANA | autism via review | Endocannabinoid signaling in the control of social behavior | May 2017 |
| Based on translational evidence, these actions of anandamide are postulated to be important in social impairment related to (i) schizophrenia, in which tempering social anxiety might be dysfunctional, as well as in (ii) ASD, where a primary deficit may be in nucleus accumbens-regulated social reward. | |||
| CBD | autism via review | Autism Spectrum Disorder and Cannabidiol: Have We Seen This Movie Before? | Nov 2018 |
| This commentary provides guidance to clinicians who care for children with ASD. We identify the current level of evidence for the safe and effective use of CBD with children diagnosed with ASD and provide guidance for clinicians who encounter this population of children and families. | |||
| CBD | autism in humans via study (n=53) | Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities | Jan 2019 |
| Parents reports suggest that cannabidiol may improve ASD comorbidity symptoms; however, the long-term effects should be evaluated in large scale studies. | |||
| CBD | autism in humans via trial (n=60) | Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study. | Oct 2018 |
| Positive Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD. | |||
| CBD | autism in humans via trial (n=53) | Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities | Jan 2019 |
| Positive Self-injury and rage attacks (n = 34) improved in 67.6% and worsened in 8.8%. Hyperactivity symptoms (n = 38) improved in 68.4%, did not change in 28.9% and worsened in 2.6%. Sleep problems (n = 21) improved in 71.4% and worsened in 4.7%. Anxiety (n = 17) improved in 47.1% and worsened in 23.5%. Adverse effects, mostly somnolence and change in appetite were mild. | |||